Literature DB >> 30118897

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Joshua F Zeidner1, Matthew C Foster2, Amanda L Blackford3, Mark R Litzow4, Lawrence E Morris5, Stephen A Strickland6, Jeffrey E Lancet7, Prithviraj Bose8, M Yair Levy9, Raoul Tibes10, Ivana Gojo11, Christopher D Gocke3, Gary L Rosner3, Richard F Little12, John J Wright12, L Austin Doyle12, B Douglas Smith3, Judith E Karp3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30118897      PMCID: PMC7169946          DOI: 10.1016/j.leukres.2018.08.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  14 in total

1.  Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Authors:  Jeffrey E Lancet; Jorge E Cortes; Donna E Hogge; Martin S Tallman; Tibor J Kovacsovics; Lloyd E Damon; Rami Komrokji; Scott R Solomon; Jonathan E Kolitz; Maureen Cooper; Andrew M Yeager; Arthur C Louie; Eric J Feldman
Journal:  Blood       Date:  2014-03-31       Impact factor: 22.113

2.  Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; B Douglas Smith; Mark J Levis; Steven D Gore; Jacqueline Greer; Catherine Hattenburg; Janet Briel; Richard J Jones; John J Wright; A Dimitri Colevas
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

3.  Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

Authors:  Judith E Karp; Antonino Passaniti; Ivana Gojo; Scott Kaufmann; Keith Bible; Tushar S Garimella; Jacqueline Greer; Janet Briel; B Douglas Smith; Steven D Gore; Michael L Tidwell; Douglas D Ross; John J Wright; A Dimitrios Colevas; Kenneth S Bauer
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

4.  Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Elizabeth Garrett-Mayer; Elihu H Estey; Michelle A Rudek; B Douglas Smith; Jacqueline M Greer; D Michelle Drye; Karen Mackey; Kathleen Shannon Dorcy; Steven D Gore; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Keith W Pratz; Douglas E Gladstone; Margaret M Showel; Megan Othus; L Austin Doyle; John J Wright; John M Pagel
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

5.  Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

Authors:  Judith E Karp; B Douglas Smith; Linda S Resar; Jacqueline M Greer; Amanda Blackford; Ming Zhao; Dwella Moton-Nelson; Katrina Alino; Mark J Levis; Steven D Gore; Biju Joseph; Hetty Carraway; Michael A McDevitt; Lorena Bagain; Karen Mackey; Janet Briel; L Austin Doyle; John J Wright; Michelle A Rudek
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

6.  Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Authors:  Joshua F Zeidner; Matthew C Foster; Amanda L Blackford; Mark R Litzow; Lawrence E Morris; Stephen A Strickland; Jeffrey E Lancet; Prithviraj Bose; M Yair Levy; Raoul Tibes; Ivana Gojo; Christopher D Gocke; Gary L Rosner; Richard F Little; John J Wright; L Austin Doyle; B Douglas Smith; Judith E Karp
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

7.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

8.  Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Amanda Blackford; B Douglas Smith; Katrina Alino; Amy Hatfield Seung; Javier Bolaños-Meade; Jacqueline M Greer; Hetty E Carraway; Steven D Gore; Richard J Jones; Mark J Levis; Michael A McDevitt; L Austin Doyle; John J Wright
Journal:  Leuk Res       Date:  2009-12-04       Impact factor: 3.156

9.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Deedra Nicolet; Kati S Maharry; Heiko Becker; Susan P Whitman; Klaus H Metzeler; Sebastian Schwind; Yue-Zhong Wu; Jessica Kohlschmidt; Mark J Pettenati; Nyla A Heerema; AnneMarie W Block; Shivanand R Patil; Maria R Baer; Jonathan E Kolitz; Joseph O Moore; Andrew J Carroll; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

Review 10.  Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.

Authors:  Joshua F Zeidner; Judith E Karp
Journal:  Leuk Res       Date:  2015-10-19       Impact factor: 3.156

View more
  9 in total

Review 1.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

2.  Heterogeneity in refractory acute myeloid leukemia.

Authors:  Sachi Horibata; Gege Gui; Justin Lack; Christin B DeStefano; Michael M Gottesman; Christopher S Hourigan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-07       Impact factor: 11.205

3.  A distinct role for recombination repair factors in an early cellular response to transcription-replication conflicts.

Authors:  Xin Shao; Amalie M Joergensen; Niall G Howlett; Michael Lisby; Vibe H Oestergaard
Journal:  Nucleic Acids Res       Date:  2020-06-04       Impact factor: 16.971

Review 4.  Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.

Authors:  Raoul Tibes; James M Bogenberger
Journal:  Front Oncol       Date:  2019-12-12       Impact factor: 6.244

Review 5.  Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML).

Authors:  Ziyang Cao; Yi Shu; Jinxia Wang; Chunxia Wang; Tienan Feng; Li Yang; Jingbo Shao; Lin Zou
Journal:  Genes Dis       Date:  2022-03-23

6.  Targeting Chromatin Regulation in Acute Myeloid Leukemia.

Authors:  Simon E Richardson; Brian J P Huntly
Journal:  Hemasphere       Date:  2021-06-01

7.  Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells.

Authors:  Michela Codini; Carmela Conte; Samuela Cataldi; Cataldo Arcuri; Andrea Lazzarini; Maria Rachele Ceccarini; Federica Patria; Alessandro Floridi; Carmen Mecca; Francesco Saverio Ambesi-Impiombato; Tommaso Beccari; Francesco Curcio; Elisabetta Albi
Journal:  Int J Mol Sci       Date:  2018-11-01       Impact factor: 5.923

Review 8.  Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use.

Authors:  Madhusmita Dhupal; Devasish Chowdhury
Journal:  Int J Nanomedicine       Date:  2020-11-19

9.  Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Authors:  Wittawat Chantkran; Ya-Ching Hsieh; Daniella Zheleva; Sheelagh Frame; Helen Wheadon; Mhairi Copland
Journal:  Cell Death Discov       Date:  2021-06-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.